Changes of IL-4,IL-10,IL-12,IL-13, IFN-γ and TGF-β in the serum of atopic dermatitis patients at different stages of the disease

doi:10.3969/j.issn.1006-7795.2017.05.001

Abstract

Abstract: Objective To investigate the changes of interleukin-4(IL-4),IL-10,IL-12,IL-13, interferon-γ (IFN-γ) and transforming growth factor-β (TGF-β) in the serum of atopic dermatitis patients at different stages of the disease, and explore their significance. Methods Seventy-nine atopic dermatitis patients at acute stage were enrolled. There were 40 cases at remission stage(remission group, RG), and 39 cases were still at acute stage after treatment(acute group, AG). The serum levels of IL-4,IL-10,IL-12,IL-13, IFN-γ and TGF-β were detected by enzyme-linked immunosorbent assay(ELISA) before and after treatment. Results There were significant differences in the serum levels of IL-4,IL-12,IL-13 and IFN-γ before and after treatment in the remission group(P<0.05). There were no significant differences in the serum levels of IL-10, TGF-β before and after treatment in the remission group(P>0.05). There were no significant differences in the serum levels of IL-4,IL-10,IL-12,IL-13, IFN-γ and TGF-β before and after treatment in the acute group(P>0.05).Conclusion Lower expression of IL-4, IL-13, and higher expression of IFN-γ, IL-12 in serum at remission stage of atopic dermatitis.

Key words: atopic dermatitis, helper T lymphocytes, interleukin, interferon-γ, transforming growth factor-β

CLC Number:

R758.23

Li Yan, Xu Wei, Cheng Haiyan, Sun Xiaoli, Li Linfeng. Changes of IL-4,IL-10,IL-12,IL-13, IFN-γ and TGF-β in the serum of atopic dermatitis patients at different stages of the disease[J]. Journal of Capital Medical University, 2017, 38(5): 635-639.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.05.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I5/635

References

[1] Renert-Yuval Y, Guttman-Yassky E. Systemic therapies in atopic dermatitis:The pipeline[J]. Clin Dermatol, 2017,35(4):387-397.
[2] Weiss D, Schaschinger M, Ristl R,et al. Ustekinumab treatment in severe atopic dermatitis:Down-regulation of T-helper 2/22 expression[J]. J Am Acad Dermatol, 2017,76(1):91-97.
[3] Sullivan M, Silverberg N B. Current and emerging concepts in atopic dermatitis pathogenesis[J]. Clin Dermatol, 2017,35(4):349-353.
[4] Vakharia P P, Chopra R, Silverberg J I. Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials[J]. Am J Clin Dermatol, 2017, Jun 17.[Epub ahead of print]
[5] Gånemo A, Svensson Å, Svedman C, et al. Usefulness of Rajka & Langeland Eczema Severity Score in Clinical Practice[J]. Acta Derm Venereol,2016, 96(4):521-524.
[6] 赵辨. 湿疹面积及严重度指数评分法[J]. 中华皮肤科杂志,2004,37(1):3-4.
[7] 李妍,徐薇,钟珊,等. 青鹏软膏治疗乏脂性湿疹疗效和皮肤屏障功能影响的自身对照研究[J]. 中华皮肤科杂志,2016,49(2):128-130.
[8] 李妍,徐薇,李邻峰. 外用糖皮质激素联合含抗菌肽保湿剂对湿疹的疗效观察[J]. 中华皮肤科杂志,2016,49(10):733-736.
[9] 李妍,徐薇,杨宝琦,等. 青鹏软膏治疗儿童局限性湿疹的多中心随机对照研究[J]. 中华皮肤科杂志,2017,50(6):412-416.
[10] Udkoff J, Waldman A, Ahluwalia J,et al. Current and emerging topical therapies for atopic dermatitis[J]. Clin Dermatol, 2017,35(4):375-382.
[11] Mashiko S, Mehta H, Bissonnette R,et al. Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis[J]. J Dermatol Sci, 2017, pii:S0923-1811(17)30701-30706.
[12] Nomura T, Kabashima K. Advances in atopic dermatitis in 2015[J]. J Allergy Clin Immunol,2016,138(6):1548-1555.
[13] Lee H S, Choi E J, Lee K S,et al. Oral administration of p-Hydroxycinnamic acid attenuates atopic dermatitis by downregulating Th1 and Th2 cytokine production and keratinocyte activation[J]. PLoS One, 2016,11(3):e0150952.
[14] 崔东源,王晓非. CCL17在类风湿关节炎患者外周血清中的表达及意义[J].中国医科大学学报,2015,44(10):913-916,920.
[15] Gittler J K, Shemer A, Suárez-Fariñas M,et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis[J]. J Allergy Clin Immunol, 2012,130(6):1344-1354.
[16] Hijnen D, Knol E F, Gent Y Y, et al. CD8⁺ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22[J]. J Invest Dermatol, 2013,133(4):973-979.
[17] Paul W E. History of interleukin-4[J]. Cytokine, 2015,75(1):3-7.
[18] Nada H A, Gomaa N I, Elakhras A, et al. Skin colonization by superantigen-producing staphylococcus aureus in egyptian patients with atopic dermatitis and its relation to disease severity and serum interleukin-4 level[J]. Int J Infect Dis, 2012,16(1):e29-e33.
[19] Kaminishi K, Soma Y, Kawa Y,et al. Flow cytometric analysis of IL-4, IL-13 and IFN-γ expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease[J]. J Dermatol Sci,2002,29(1):19-25.
[20] Wang A X, Xu Landén N. New insights into T cells and their signature cytokines in atopic dermatitis[J]. IUBMB Life, 2015,67(8):601-610.
[21] Metwally S S, Mosaad Y M, Abdel-Samee E R, et al.IL-13 gene expression in patients with atopic dematitis:relation to IgE level and to disease severity[J].Egypt J Immunol, 2004,11(2):171-177.
[22] Yu Y, Zhang Y, Zhang J, et al. Impaired Toll-like receptor 2-mediated Th1 and Th17/22 cytokines secretion in human peripheral blood mononuclear cells from patients with atopic dermatitis[J]. J Transl Med, 2015,13:384.
[23] 陈浩, 郭在培.特应性皮炎中细胞因子的研究进展[J]. 中国麻风皮肤病杂志,2008,24(6):460-463.
[24] Shida K, Koizumi H, Shiratori I, et al. High serum levels of additional IL-18 forms may be reciprocally correlated with IgE levels in patients with atopic dermatitis[J]. Immunol Lett, 2001,79(3):169-175.
[25] Katsunuma T,Kawahara H,Yuki K,et al.Impaired interferon-gamma production in a subset population of severe atopic dermatitis[J].Int Arch Allergy Immunol,2004,134(3):240-247.
[26] Lesiak A, Zakrzewski M, Przybyłowska K, et al. Atopic dermatitis patients carrying G allele in -1082 G/A IL-10 polymorphism are predisposed to higher serum concentration of IL-10[J]. Arch Med Sci, 2014,10(6):1239-1243.
[27] Hussein P Y, Zahran F, Ashour Wahba A,et al. Interleukin 10 receptor alpha subunit (IL-10RA) gene polymorphism and IL-10 serum levels in Egyptian atopic patients[J]. J Investig Allergol Clin Immunol, 2010,20(1):20-26.
[28] Zhang Y Y, Wang A X, Xu L,et al. Characteristics of peripheral blood CD4⁺ CD25⁺ regulatory T cells and related cytokines in severe atopic dermatitis[J]. Eur J Dermatol, 2016,26(3):240-246.
[29] 赵宏丽,赵俊芳,李孟娟. CD4⁺ IL-10⁺ 调节性T细胞在特应性皮炎病人中的改变[J].天津医药,2012,40(8):821-822.
[30] Dong C, Virtucio C, Zemska O,et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase Inhibitors:selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes[J]. J Pharmacol Exp Ther, 2016,358(3):413-422.
[31] Bissonnette R, Papp K A, Poulin Y,et al. Topical tofacitinib for atopic dermatitis:a phase Ⅱa randomized trial[J]. Br J Dermatol, 2016,175(5):902-911.